Navigation Links
Osteotech Announces First Quarter 2010 Financial Results Release and Conference Call
Date:5/3/2010

EATONTOWN, N.J., May 3 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that the Company's first quarter ended March 31, 2010 financial results will be released before the market opens on Monday, May 10, 2010.  The management team of Osteotech will host a conference call and webcast on Monday, May 10, 2010, at 9:00 a.m. (EDT) to discuss the Company's financial results, recent accomplishments and 2010 goals.  The call can be accessed by dialing 1-866-783-2142 (domestic) or 1-857-350-1601 (international) and indicating access code 45753886.  A replay of the call will be available two hours after completion of the live call through midnight, Monday, May 24, 2010 by dialing 1-888-286-8010 and indicating access code 86998695.

A live, listen-only webcast of the conference call will also be available at the Company's investor site at http://www.osteotech.com on the Financial Highlights page.  A replay of the conference call and the question/answer session will be available at the Company's website for approximately 14 days following the call.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
4. Osteotech Reports Third Quarter 2009 Financial Results
5. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
6. Osteotech Announces Preliminary Fourth Quarter 2009 Revenue
7. Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results
8. Osteotechs MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... -- New research provides evidence that an old drug may provide ... released today that will be presented at the American ... Boston , April 22 to 28, 2017. ... the oral drug levodopa has long been considered the gold ... disease progresses, the effects of the medication can partially wear ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after thirteen ... in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl appearances ... yards by a quarterback (6,109) and the most rushing yards by a quarterback in ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
Breaking Medicine News(10 mins):